AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02229149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
Description: physician's choice of chemotherapy:~* Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~* Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~* Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~* Docetaxel 75 mg/m2 IV every 3 weeks; OR~* Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.
Study NCT02229149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
Description: physician's choice of chemotherapy:~* Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~* Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~* Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~* Docetaxel 75 mg/m2 IV every 3 weeks; OR~* Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.
Study NCT01334125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000 mg once daily by mouth for 9 months
Study NCT04541693 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stem revision
Description: Only the stem requires revision
Study NCT03531827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX101
Description: CRLX101 is a nanoparticle-drug conjugate (NDC) comprised of a linear cyclodextrin-polyethylene glycol-base polymer conjugated to multiple 2 (S)-camptothecin (CPT) molecules (Poly-CD-PEG-Camptothecin)
Study NCT02216981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Study NCT02216981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Study NCT01334125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules once daily by mouth for 9 months
Study NCT04283045 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JASPER Plus+
Description: JASPER Plus+ refers to direct instruction of social communication targets of pointing to share, showing gesures, and give to share gestures, and play targets at the child's target play level.~JASPER Plus+ will occur at a table top with repeated trials of instruction until the child can produce the desired behavior on their own.
Study NCT02006303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Green light PVP
Description: The green light laser has a wavelength of 532 nm which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. The procedure uses the technology of high-powered laser light combined with fiber optics to vaporize the overgrowth of prostate cells quickly and accurately. As the surgeon directs the laser at the prostate, the intense pulses of light emitted from the fiber are absorbed by the blood. Within moments, the temperature of the blood becomes so great it causes the nearby cells to vaporize. Once the procedure is completed, patients have immediate post-operative symptom relief and dramatic improvements in symptoms, urinary flow rates, and bladder emptying.
Study NCT02006303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostatic artery embolization
Description: Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
Study NCT02907697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Steps-Drug Use
Study NCT02907697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Education
Study NCT00894751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: dexmedetomidine general anesthesia for MRI
Study NCT00894751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol general anesthesia for MRI
Study NCT02451423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg Given IV
Study NCT01593735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2748
Description: MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment
Study NCT03087123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: P-Mobile App
Description: The behavioral strategies are based on Social Cognitive Theory. The following topics will be covered: self-monitoring, goal setting, stimulus control, making time for exercise, exercising in- and outdoors, problem-solving, reinforcing PA, reducing sedentary behaviors, relapse prevention, parental modeling, lifestyle exercise, self-efficacy, self-management, parental PA modeling, parental co-participation, and establishing PA rules. Parents will be provided with adapted step goals (based on principles of shaping). Text messages will be designed to prompt PA, remind parents of concepts from the lessons, and motivate behavioral change.
Study NCT02440529 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Discussion
Study NCT02440529 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal Group
Description: Detailed Discussion
Study NCT01593735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, once daily for 7 days
Study NCT01140659 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Video-assisted sympathectomy
Description: All participants were randomized into two groups of 20 patients (G3 and G4) and underwent video-assisted sympathectomy, being followed for 12 months. During this period, the subjects completed a questionnaire about quality of life and carried out the measurements of sweat by VapoMeter.
Study NCT00510796 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview regarding perception of pain and the benefits and barriers to the combined screening.
Study NCT04253197 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: Pregnant women in 3rd trimester with anterior placenta previa and lower cesarean section scar. Ultrasound was done and according to parameters of the morbidly adherent placenta, a staging system was conducted.
Study NCT00649129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride ER Tablets 10 mg
Description: 2x10mg, single dose fasting
Study NCT00649129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ditropan XL® Tablets 10 mg
Description: 2x10mg, single dose fasting
Study NCT02541539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus casei Zhang
Description: This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
Study NCT02541539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
Study NCT01874327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baby JASPER
Description: Intervention focuses on core deficits of joint attention, play, engagement, and regulation embedded within AEPS curriculum
Study NCT01874327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Baby Classroom
Description: Assessment, Education and Programming System (AEPS) for Infants and Children curriculum focused on early developmental milestones in fine and gross motor, cognitive, adaptive and social areas
Study NCT04178200 — intervention group
Intervention type: DRUG
Intervention: Lidocaine 2% Injectable Solution 0.75 ml
Description: 0.75 ml of Lidocaine will be added to the anesthetic solution.
Study NCT04178200 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine Hcl 0.5% Inj 0.75 ml
Description: 0.75 ml of Bupivacaine will be added to the anesthetic solution.
Study NCT04178200 — intervention group
Intervention type: DRUG
Intervention: Lidocaine 2% Injectable Solution 1.5 ml
Description: 1.5 ml of Lidocaine will be added to the anesthetic solution.
Study NCT04178200 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine Hcl 0.5% Inj 1.5 ml
Description: 1.5 ml of Bupivacaine will be added to the anesthetic solution.
Study NCT01579019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1500 mg po bid, 24 or 26 weeks
Study NCT01579019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO5024048
Description: 1000 mg po bid, 24 or 26 weeks
Study NCT01579019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir
Description: 100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
Study NCT01579019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
Study NCT01579019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc qw, 24 or 26 weeks
Study NCT01579019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc qw, 24 or 26 weeks
Study NCT01579019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg po daily, 24 or 26 weeks
Study NCT01579019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg po daily, 24 or 26 weeks
Study NCT01579019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: 100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
Study NCT01579019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
Study NCT01114620 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arepanrix™
Description: Intramuscular administration, one dose
Study NCT03590743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Active anticoagulation with apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily to complete a total of 3 months treatment.
Study NCT03590743 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: apixaban matching placebo 2 tablets twice daily for 7 days followed by one tablet twice daily to complete a total of 3 months.
Study NCT02313558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dentifrice Containing Ilex Rotunda Thunb
Description: Use the dentifrice to brush teeth twice a day for 12 weeks
Study NCT02313558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control dentifrice
Description: Use the dentifrice to brush teeth twice a day for 12 weeks
Study NCT03505996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS1001
Description: Monoclonal antibody
Study NCT01251068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: near infrared spectroscopy: invos 5100
Description: duration:six hours
Study NCT04408001 — intervention group
Intervention type: OTHER
Intervention: Clinical interview
Description: At each study visit, participants will be questioned by a physician about their persistent symptoms or the existence of intercurrent infections that may resemble COVID-19.
Study NCT04408001 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: At each study visit,~* 1 EDTA tube for complete blood count~* 3 dry tubes with gel for serology, serum neutralisation test and serum library~* 1 cell preparation tube for the separation of immune cells within the circulating blood will be collected.
Study NCT01251068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVOS 5100
Description: NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
Study NCT01251068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: near infrared spectroscopy device
Description: NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
Study NCT03118063 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of pain by algometry
Description: Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
Study NCT03118063 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of pain by algometry
Description: Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
Study NCT04408001 — intervention group
Intervention type: BIOLOGICAL
Intervention: Saliva collection
Description: At each study visit, a saliva sample will be collected for the determination of IgA antibodies.
Study NCT00799071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: posaconazole (PSZ)
Description: Intake of PSZ oral suspension 40mg/ml twice daily with food. Starting dose is based on bodyweight. The dosage will be adjusted if the exposure is not adequate based on PSZ trough level on Day 10 and 20.
Study NCT04477850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Specified dose on specified days
Study NCT03789643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-251
Description: Active drug tablets containing JTT-251
Study NCT03789643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching in appearance to the active drug tablets
Study NCT02555007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Study NCT04447781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4800
Description: - Manufacturer: Inovio Pharmaceuticals Inc.
Study NCT02042599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedation with sevoflurane during 48-hr in ICU
Study NCT03224143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doll Therapy Intervention
Description: Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the doll in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the doll in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the doll after the second request, the N will not insist and she will leave. If the doll will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P.
Study NCT03224143 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active control group (SI)
Description: Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the cube in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the cube in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the cube after the second request, the N will not insist and she will leave. If the cube will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P.
Study NCT00510393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus eluting coronary stent system
Study NCT00510393 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MULTILINK VISION coronary stent system
Study NCT04261374 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of sublingual microcirculation
Description: Measurement of sublingual microcirculation
Study NCT00337493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: Concentration-controlled
Study NCT00337493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: 1g po bid
Study NCT04447781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: - Manufacturer: Inovio Pharmaceuticals Inc.
Study NCT00337493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine or tacrolimus
Description: Reduced
Study NCT00337493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine or tacrolimus
Description: Standard, as prescribed
Study NCT04447781 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA® 2000
Description: - Manufacturer: Inovio Pharmaceuticals Inc.
Study NCT04447781 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline-sodium citrate (SSC) buffer
Description: - Manufacturer: Inovio Pharmaceuticals Inc.
Study NCT03658629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NanoFlu (Quad-NIV)
Description: 2018-2019 Investigational Quadrivalent Seasonal Influenza Vaccine
Study NCT03658629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M Adjuvant
Description: Adjuvant
Study NCT03658629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03658629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone HD
Description: 2018-2019 Licensed Trivalent Seasonal Influenza Vaccine
Study NCT03658629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flublok Quadrivalent
Description: 2018-2019 Licensed Quadrivalent Seasonal Influenza Vaccine
Study NCT03658629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: 2018-19 Licensed Seasonal Influenza Vaccine
Study NCT04435730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum level of Mac 2 binding protein
Description: Serum levels of Mac 2 binding protein will be measured for all the study subjects using Enzyme-Linked Immuno sorbent Assay (ELISA).~2 ml of venous blood will be collected from patients and controls under complete aseptic conditions in a plain tube. Sample will be allowed to clot for 15-30 min at room temperature and then centrifuged at 2500 rpm for 10-15 min. Serum will be separated and stored at -20 C or lower till time of assessment.
Study NCT03280927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jublia®
Description: Jublia® topical solution
Study NCT01110070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChonDux
Description: Comparison of ChonDux plus microfracture to microfracture only
Study NCT04435730 — intervention group
Intervention type: DEVICE
Intervention: musculoskeletal ultrasound
Description: MSUS examination will be performed for patients of all groups and control group.Gray scale (GSUS) and power Doppler (PDUS) at joints levels and entheses will be performed with the same transducer of My Lab Seven Crystalline esaote machine.
Study NCT02403531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
Study NCT02403531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
Study NCT02403531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
Study NCT02403531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
Study NCT02403531 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: definitive radiotherapy
Study NCT02403531 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: definitive radiotherapy
Study NCT02909101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Cognitive Training (ACT)
Description: Cognitive training games
Study NCT02909101 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Training (CON)
Description: Cognitive training games